Dataset Information

Kojic Acid Peptide: A New Compound with Anti-Tyrosinase Potential.

ABSTRACT:

Background

Kojic acid was used for decades in the cosmetic industry as an antimelanogenic agent. However, there are two major drawbacks of Kojic acid, one is cytotoxicity and second are instability on storage. These limitations led the scientist to synthesize the active Kojic acid peptides.

Objective

In the present study, we synthesize and investigate the effect of five Kojic acid peptides to overcome the limitation of Kojic acid.

Methods

The peptide was analyzed and purified by high-performance liquid chromatography and matrix-assisted laser desorption ionization time of flight mass spectroscopy. Further, the tyrosinase activities of the Kojic acid and Kojic acid peptides were compared. The toxicity was measured and the melanin content is recorded in B16F10 mouse melanoma cells.

Results

Maximum tyrosinase activity was measured by Kojic acid peptides. Therefore, Kojic acid peptides were subjected to melanin assay and cytotoxicity assay and finally the stability of the Kojic acid peptide was measured.

Conclusion

It was observed that this newly synthesized Kojic acid peptide is stable and potent to inhibit the tyrosinase activity and melanin content of B16F10 mouse melanoma cells without exhibiting cell toxicity. Together, these preliminary results suggest that a further exploration is being needed to establish Kojic acid peptide as antimelanogenic agent.

SUBMITTER: Singh BK

PROVIDER: S-EPMC5064183 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Kojic Acid Peptide: A New Compound with Anti-Tyrosinase Potential.

Singh Birendra Kumar BK Park Seok Hoon SH Lee Hyang-Bok HB Goo Young-Aae YA Kim Hyoung Shik HS Cho Seung Hee SH Lee Jeong Hun JH Ahn Ghe Whan GW Kim Jin Pyo JP Kang Su Myoung SM Kim Eun-Ki EK

Annals of dermatology 20160930 5

<h4>Background</h4>Kojic acid was used for decades in the cosmetic industry as an antimelanogenic agent. However, there are two major drawbacks of Kojic acid, one is cytotoxicity and second are instability on storage. These limitations led the scientist to synthesize the active Kojic acid peptides.<h4>Objective</h4>In the present study, we synthesize and investigate the effect of five Kojic acid peptides to overcome the limitation of Kojic acid.<h4>Methods</h4>The peptide was analyzed and purifi ...[more]

PMID: 27746633

Similar Datasets

Project description:ObjectivesLignosulfonic acid (LA), a low-cost lignin-derived polyanionic macromolecule, was extensively studied for its anti-HIV and anti-HSV activity in various cellular assays, its mechanism of viral inhibition and safety profile as potential microbicide.ResultsLA demonstrated potent inhibitory activity of HIV replication against a wide range of R5 and X4 HIV strains and prevented the uptake of HIV by bystander CD4+ T cells from persistently infected T cells in vitro (IC50: 0.07 - 0.34 ?M). LA also inhibited HSV-2 replication in vitro in different cell types (IC50: 0.42 - 1.1 ?M) and in rodents in vivo. Furthermore, LA neutralized the HIV-1 and HSV-2 DC-SIGN-mediated viral transfer to CD4+ T cells (IC50: ~1 ?M). In addition, dual HIV-1/HSV-2 infection in T cells was potently blocked by LA (IC50: 0.71 ?M). No antiviral activity was observed against the non-enveloped viruses Coxsackie type B4 and Reovirus type 1. LA is defined as a HIV entry inhibitor since it interfered with gp120 binding to the cell surface of T cells. Pretreatment of PBMCs with LA neither increased expression levels of cellular activation markers (CD69, CD25 and HLA-DR), nor enhanced HIV-1 replication. Furthermore, we found that LA had non-antagonistic effects with acyclovir, PRO2000 or LabyA1 (combination index (CI): 0.46 - 1.03) in its anti-HSV-2 activity and synergized with tenofovir (CI: 0.59) in its anti-HIV-1 activity. To identify mechanisms of LA resistance, we generated in vitro a mutant HIV-1 NL4.3LAresistant virus, which acquired seven mutations in the HIV-1 envelope glycoproteins: S160N, V170N, Q280H and R389T in gp120 and K77Q, N113D and H132Y in gp41. Additionally, HIV-1 NL4.3LAresistant virus showed cross-resistance with feglymycin, enfuvirtide, PRO2000 and mAb b12, four well-described HIV binding/fusion inhibitors. Importantly, LA did not affect the growth of vaginal Lactobacilli strains.ConclusionOverall, these data highlight LA as a potential and unique low-cost microbicide displaying broad anti-HIV and anti-HSV activity.

Dataset Information

Kojic Acid Peptide: A New Compound with Anti-Tyrosinase Potential.

Background

Objective

Methods

Results

Conclusion

Publications

Kojic Acid Peptide: A New Compound with Anti-Tyrosinase Potential.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets